
Tirzepatide 20mg Metabolism
-22% weight. GIP + GLP-1.
The latest-generation dual agonist. GIP + GLP-1 combined for weight loss documented at -22% over 72 weeks (SURMOUNT-1). Outperforms Semaglutide head to head. The future of targeted weight loss.
Research protocols start at: 25 units, i.e. 2.5 mg per week (vial prepared with 2 ml of water).
20 mg = what the vial contains, not the dose.See the preparation
Research Use Only (RUO) · Prohibited for human or veterinary use.
Key facts
Tirzepatide 20mg is the format for the intermediate steps (5 to 10mg per week), giving access to the GLP-1/GIP dual agonism documented by SURPASS and SURMOUNT without heavy volumetric commitment. This vial covers 2 to 4 weeks at the maintenance level of 5 to 10 mg per week. For researchers discovering the molecule or calibrating a first protocol, the 10mg format (start at 2.5mg) validates individual tolerance, adjusts titration to subject physiology, and measures early metabolic markers (fasting glucose, HbA1c, body mass, waist circumference, lipids) before committing to a long cycle. Its compact format also minimizes financial risk if discontinuation is decided early in the cycle.
In detail
Range positioning20mg covers the 5 to 10mg steps, between the 10mg (start at 2.5mg) and the 15mg (standard SURMOUNT-1 target dose), 30mg (long-cycle, 3 to 6 weeks at the maintenance level of 5 to 10 mg per week), or 60mg (mega-cycle, 6 to 12 weeks at the same level). The 20mg vial, reconstituted with 2 mL bacteriostatic water, delivers 10 mg/mL: 25 units = 2.5 mg; 50 units = 5 mg; 75 units = 7.5 mg. Caution: twice as concentrated as the 10mg vial (5 mg/mL), do not reuse its markings. At target dose 10mg/week (SURMOUNT-1 plateau week 13-16), one vial covers exactly 2 full weeks; at 5mg/week (plateau week 5-8) it covers 4 weeks. To start at 2.5mg, the 10mg vial is the right format: within 28 days after reconstitution the 20mg would not be finished. The format thus suits both calibration and short-segment validation equally.
Protocol and preparation
| Water added | Concentration | Reading marker |
|---|---|---|
| 2 ml | 10 mg/ml | 10 UI = 1 mg |
| 3 ml | 6,67 mg/ml | 40 UI = 2,67 mg |
The volume of water does not change the product, only its concentration. Introduce the water slowly along the vial wall, never directly onto the lyophilisate, then swirl without shaking. Markers given on a 1 ml syringe graduated in 100 units.
Asepsis
Disinfect surfaces and stoppers (70% alcohol).
Solvent
Draw the required volume of bacteriostatic water.
Introduction
Inject gently against the vial wall (avoid direct jet on powder).
Solubilization
Roll the vial gently. Do not shake vigorously (degradation risk).
Solution storage Once reconstituted: 2-8°C (refrigerator).
Warning Theoretical tool for chemical handling. Does not constitute medical advice.
Open the dilution calculator- The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
- The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
- The vial carries no individual label. That is our standard packaging, not a downgraded vial.
- After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
- The parcel is plain. Nothing on the outside indicates the contents or the brand name.
What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.
The SURMOUNT-1 reference protocol (Jastreboff 2022, NEJM) is the usual template. Weekly titration: 2.5mg W1-4, 5mg W5-8, 7.5mg W9-12, 10mg W13-16, 12.5mg W17-20, 15mg W21+. The 20mg vial is built for the 5mg-and-above steps: to start at 2.5mg, take the 10mg vial.
Reconstitution2 mL of bacteriostatic water, i.e. 10 mg/mL. This vial is twice as concentrated as the 10mg (5 mg/mL): never reuse its markings. 25 units = 2.5 mg; 50 units = 5 mg; 75 units = 7.5 mg; 100 units = 10 mg (the full U100 syringe).
Option A5mg/week step (W5-8 SURMOUNT-1): draw 50 units (0.5 mL). One vial = 4 doses = 4 weeks, right within the 28-day window after reconstitution.
Option B7.5mg/week step (W9-12): draw 75 units (0.75 mL). One vial = 2 doses of 7.5mg, with 5mg (50 units) left for a third week at the lower step or to combine with the next vial.
Option C10mg/week step (W13-16): draw 100 units (1 mL, the full syringe). One vial = 2 weeks.
Injection siteRotate across 4 abdominal subcutaneous zones (right upper, right lower, left upper, left lower quadrants), minimum 2.5 cm from navel. Alternate weekly to prevent lipohypertrophy. Anterolateral thigh and flank are valid alternatives. Bevel up, angle 45-90 degrees depending on skinfold thickness. Aspirate if unsure, inject slowly (5-10 seconds), hold 10 seconds before withdrawal.
Minimum monitoringWeekly weight at fixed time, waist every 15 days, fasting glucose every 4 weeks (or continuous via CGM for advanced protocols), HbA1c at W0, W12, W24. Daily adverse event journal for the first 4 weeks (nausea, satiety, fatigue, bowel movements).
Technical data
- Reconstitution
- 2 ml d'eau → 10 mg/ml. 25 UI = 2,5 mg ; 50 UI = 5 mg ; 75 UI = 7,5 mg. Attention : deux fois plus concentré que le flacon de 10 mg (5 mg/ml), ne pas reprendre ses repères.
- Peptide sequence
- YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS-NH2 (X = Aib ; lysine acylée)
- Molecular formula
- C225H348N48O68
- Molecular weight
- 4813.45 g/mol
- CAS number
- 2023788-19-2
- Physical form
- Poudre lyophilisée blanche
- Recommended solubility
- Eau bactériostatique, NaCl 0.9%, acide acétique 0.1%
- Storage conditions
- Au réfrigérateur (+2 à +8 °C), à l'abri de la lumière. En poudre, possible au congélateur pour une conservation longue. Une fois préparé : réfrigérateur, jamais au congélateur.
- Use
- Research reagent, in vitro only (RUO)
Storage & handling
Lyophilized tirzepatide stability is robust as long as the cold chain is maintained. The product stores up to 24 months at 2-8 °C, protected from light in its original packaging. Freezing below -20 °C, though sometimes practiced for extended stockpiles, adds no documented benefit for the intact peptide and introduces freeze-thaw cycle risk if storage is unstable. After reconstitution with bacteriostatic water, the solution stores for 21 to 28 days at 2-8 °C, still protected from light. The 0.9% benzyl alcohol in bacteriostatic water preserves microbiological sterility but does not halt chemical peptide degradation, which continues slowly even under refrigeration. Dominant degradation pathways for tirzepatide are methionine oxidation (Met27), asparagine deamidation and glutamine deamidation, along with oligomer formation via hydrophobic interactions involving the C20 acyl chain. A 5-10% activity loss after 28 days is expected, usable in research but to be factored into dose-response calculations over extended cycles. In the laboratory, a few operational rules are essential. (1) Minimize fridge entries/exits: every thermal shock accelerates degradation. Remove the vial just before sampling, return to cold storage within 10 minutes. (2) Never shake vigorously: the C20 chain readily generates oligomers if the solution is subjected to shear (shaker, vortex). Tilt gently or let dissolve spontaneously. (3) Light protection: amber glass vials from original packaging are effective; if transferring to clear tubes, wrap in aluminum. (4) Document the cold chain with a temperature logger on the dedicated peptide fridge, with SMS alert on threshold breach. In cohort production, a strict dating protocol is required. Label each reconstituted vial with date, time, final concentration, initial lot, and operator initials. Plan samplings to exhaust the vial before day 28 as priority, minimizing reject percentage. For long cycles (> 8 weeks), prefer volumetric formats adapted to cycle duration (30mg or 60mg) rather than chaining 10 or 15mg reconstitutions, which multiply manipulations and contamination risks. The economical format matched to cycle length is the best anti-degradation and anti-waste strategy.
Mechanism of action
Tirzepatide is the first marketed dual incretin-mimetic agonist. Its 39-residue sequence derives from native human GIP (Glucose-dependent Insulinotropic Polypeptide), with engineered modifications that confer simultaneous high affinity at two G-protein-coupled receptors: GLP-1R and GIPR. Coskun and colleagues (Mol Metab 2018) described the rational design: Aib substitutions at positions 2 and 20 blocking DPP-4 cleavage, and a C20 diacid fatty-acyl chain attached to Lys20 via a gamma-glutamate linker that anchors the molecule to serum albumin and extends the half-life to roughly 117 hours in humans.
Tirzepatide biology is not simply the sum of GLP-1 plus GIP activity. The GIPR-biased sequence (picomolar-range EC50 at GIPR, sub-nanomolar at GLP-1R) creates a qualitatively distinct signaling signature. Willard et al. (JCI Insight 2020) demonstrated that tirzepatide recruits beta-arrestin less strongly at GLP-1R than native GLP-1, producing a bias toward Galpha-s / cAMP signaling that may limit receptor desensitization. At GIPR, conversely, tirzepatide behaves as a full agonist. This signaling architecture partly explains the clinical metabolic superiority observed over single GLP-1 agonists.
The GIP arm adds mechanisms absent from single agonists. In adipose tissue, GIPR activation stimulates postprandial lipogenesis and triglyceride clearance while improving insulin sensitivity in subcutaneous adipocytes. In the central nervous system, GIPR neurons in the arcuate and paraventricular nuclei modulate appetite additively with GLP-1R neurons. Preclinical models (GIPR-KO mice, obese rats) suggest that GIP/GLP-1 co-activation increases thermogenic energy expenditure through brown adipose tissue, contributing to weight loss beyond caloric restriction.
At the pancreatic level, the incretin effect is potentiated synergistically: tirzepatide administration in type 2 diabetic subjects triggers glucose-dependent insulin secretion exceeding a reference GLP-1 mono-agonist, without clinical hypoglycemia (Heise 2022 Diabetes Care). GLP-1 glucagonostatic action stabilizes fasting glycemia. Gastric emptying is also slowed, contributing to satiety but demanding attention to drug interactions and gastrointestinal discomfort during rapid titrations.
Pharmacokinetics justify the weekly regimen. Cmax is reached 24-72 hours post-injection depending on dose, terminal half-life 117 hours, steady-state achieved within 4 weeks on a fixed weekly dose. Clearance is essentially proteolytic (no significant CYP450 biotransformation), limiting pharmacokinetic interactions. In research contexts this pharmacokinetic window is precious: weekly administration produces near-stationary plasma concentrations, facilitating protocol standardization and reproducibility of cohort measurements.
Studies and references
The tirzepatide clinical program spans two armsType 2 diabetes (SURPASS) and obesity without diabetes (SURMOUNT). Phase III trial density is substantial and positions the molecule as one of the best-documented incretin agents to date.
SURPASS-1 (Rosenstock 2021, Lancet) compared tirzepatide 5/10/15mg weekly to placebo in 478 drug-naive T2D patients over 40 weeks. HbA1c reductions: -1.87% (5mg), -1.89% (10mg), -2.07% (15mg) vs -0.04% placebo. Weight loss: -7.0 to -9.5 kg dose-dependent. SURPASS-2 (Frias 2021, NEJM) was the pivotal head-to-head trial against semaglutide 1mg in 1879 patients over 40 weeks. Tirzepatide 15mg produced HbA1c reduction -2.30% vs -1.86% for semaglutide 1mg, and weight loss -11.2 kg vs -5.7 kg. This trial established the metabolic superiority of the dual agonist over the reference GLP-1 mono-agonist.
SURPASS-3 (Ludvik 2021) added tirzepatide to metformin vs insulin degludec in 1437 patients over 52 weeks: marked superiority in HbA1c reduction and weight loss, with fewer hypoglycemia events. SURPASS-4 (Del Prato 2021, Lancet) extended evaluation to high cardiovascular risk patients over 104 weeks: durable HbA1c and weight reductions, reassuring cardiovascular profile. SURPASS-5 (Dahl 2022, JAMA) tested addition to insulin glargine: HbA1c -2.40% (15mg), weight -10.9 kg, substantial metabolic improvement.
The SURMOUNT program targets obesity without diabetes. SURMOUNT-1 (Jastreboff 2022, NEJM) enrolled 2539 adults BMI >= 30 (or >= 27 with comorbidities) over 72 weeks. Mean weight loss: -15.0% (5mg), -19.5% (10mg), -20.9% (15mg) vs -3.1% placebo. 50.1% of 15mg patients reached >= 20% weight loss, 36.2% reached >= 25%.
SURMOUNT-2 (Garvey 2023, Lancet) validated the effect in diabetic obese patients (-13.4% @15mg over 72 weeks). SURMOUNT-3 (Wadden 2023, Nat Med) showed that after a 12-week intensive diet lead-in, adding tirzepatide 10/15mg generated -18.4% additional loss over 72 weeks vs +2.5% placebo. SURMOUNT-4 (Aronne 2024, JAMA) tested withdrawal: after 36 weeks of maximal tirzepatide followed by 52 weeks of maintenance or discontinuation, the discontinuation group regained 14.0% of body weight while the maintenance group lost an additional 5.5%. Practical conclusion: ongoing therapy is required to preserve benefit, consistent with obesity as a chronic disease.
Ancillary data support systemic benefits. SURPASS-CVOT (ongoing cardiovascular trial, results expected 2025-2026) will compare tirzepatide to dulaglutide in 13299 high-CV-risk T2D patients. SYNERGY-NASH (Loomba 2024, NEJM) documented MASH resolution without fibrosis worsening in 51.8% of tirzepatide 10mg patients vs 9.8% placebo. Effects on sleep apnea (SURMOUNT-OSA, Malhotra 2024 NEJM) show a 55% reduction in apnea-hypopnea index at 52 weeks. These data sketch a cross-cutting therapeutic profile few agents share.
In research these references structure protocol designTitration regimens used in trials (2.5mg weeks 1-4 then +2.5mg every 4 weeks to target dose) serve as a methodological framework for exploratory cohorts, and stopping criteria (severe gastrointestinal events, pancreatitis, hypersensitivity reactions) inform exclusion criteria for observational work.
Similar peptides
Versus semaglutide (GLP-1 mono-agonist): head-to-head superiority demonstrated in SURPASS-2 (Frias 2021 NEJM). Tirzepatide 15mg beats semaglutide 1mg by +0.44% additional HbA1c and +5.5 kg additional weight loss. The GIP arm contributes measurably to visceral fat and energy expenditure. Limit: slower titration (5 steps to 15mg) and stricter gastrointestinal tolerance in the first weeks.
Versus retatrutide (GLP-1/GIP/GCGR triple agonist): retatrutide adds a glucagon arm that stimulates hepatic thermogenesis and lipolysis. Phase II data (Jastreboff 2023 NEJM) show -24.2% at 12mg/48w vs -20.9% for tirzepatide 15mg/72w, a notable gap. But retatrutide is newer, with fewer long-term data, and the GCGR component demands heightened vigilance on hepatic function. Tirzepatide retains the advantage of clinical maturity (>400 publications) and better-mapped tolerance profile.
Versus liraglutide 3mg (Saxenda): liraglutide is a daily GLP-1 mono-agonist with -8% weight loss over 56 weeks (Pi-Sunyer 2015 NEJM SCALE). Tirzepatide 15mg weekly produces -20.9% over 72 weeks, an absolute gain of >12 percentage points. The posology advantage (1 weekly injection vs 1 daily) and 2.5x superior efficacy make liraglutide obsolete as first-line weight loss agent.
Versus dulaglutide (Trulicity): dulaglutide is a weekly GLP-1 agonist with modest weight loss (-3 to -4 kg at 1.5mg). Tirzepatide is 4-5x superior on weight outcomes. Direct comparison awaits SURPASS-CVOT (2025-2026 results) for cardiovascular events.
Versus basal insulin: SURPASS-3 and SURPASS-5 show that adding tirzepatide to antidiabetic therapy outperforms titrating basal insulin, without weight gain or hypoglycemia. Insulin remains essential in type 1 diabetes and acute type 2 decompensation, but as a type 2 intensification agent, tirzepatide is superior.
Versus bupropion-naltrexone (Contrave/Mysimba), orlistat (Xenical), phentermine-topiramate (Qsymia): these agents produce 3-10% weight loss and are eclipsed by tirzepatide (2-7x more effective by comparison). Their residual advantages: oral form, much lower cost, no injection requirement.
Research positioning: tirzepatide is today's peptide of choice for exploratory protocols combining maximal metabolic efficacy and documented tolerance profile. Its data maturity surpasses retatrutide's and rivals semaglutide's, while offering a higher intensity of effect than the mono-agonist.
Frequently asked questions
Why is tirzepatide called a "dual agonist" and what does it change in practice?
What volume of bacteriostatic water should be used to reconstitute a tirzepatide vial?
How long can reconstituted tirzepatide be stored, and what signs indicate degradation?
Why must tirzepatide be titrated progressively?
What are key drug interactions and contraindications for tirzepatide?
Can tirzepatide be combined with other research peptides (BPC-157, TB-500, CJC-1295)?
Which format should I choose for a long cohort protocol (16+ weeks)?
Why should tirzepatide never be mixed in the same syringe as insulin or another peptide?
The complete guideTirzepatide: complete guide to the GLP-1R / GIPR co-agonist in preclinical researchTechnical dossier on tirzepatide for research use: hybrid GIP-GLP-1 structure, dual GLP-1R/GIPR activation, pharmacokinetics, incretin synergy, DIO and ZDF models, QC analytics. Strictly RUO use.Read the guide Also read:Tirzepatide: the dedicated page
